These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 32421118)
1. Huntington's disease genotype suppresses global manganese-responsive processes in pre-manifest and manifest YAC128 mice. Pfalzer AC; Wilcox JM; Codreanu SG; Totten M; Bichell TJV; Halbesma T; Umashanker P; Yang KL; Parmalee NL; Sherrod SD; Erikson KM; Harrison FE; McLean JA; Aschner M; Bowman AB Metallomics; 2020 Jul; 12(7):1118-1130. PubMed ID: 32421118 [TBL] [Abstract][Full Text] [Related]
2. YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes. Wilcox JM; Pfalzer AC; Tienda AA; Debbiche IF; Cox EC; Totten MS; Erikson KM; Harrison FE; Bowman AB Neurotoxicology; 2021 Dec; 87():94-105. PubMed ID: 34543681 [TBL] [Abstract][Full Text] [Related]
3. Striatal Cholesterol Precursors Are Altered with Age in Female Huntington's Disease Model Mice. Pfalzer AC; Wages PA; Porter NA; Bowman AB J Huntingtons Dis; 2019; 8(2):161-169. PubMed ID: 30958310 [TBL] [Abstract][Full Text] [Related]
4. Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism. Madison JL; Wegrzynowicz M; Aschner M; Bowman AB PLoS One; 2012; 7(2):e31024. PubMed ID: 22363539 [TBL] [Abstract][Full Text] [Related]
5. Manganese-induced hyperactivity and dopaminergic dysfunction depend on age, sex and YAC128 genotype. Wilcox JM; Consoli DC; Paffenroth KC; Spitznagel BD; Calipari ES; Bowman AB; Harrison FE Pharmacol Biochem Behav; 2022 Feb; 213():173337. PubMed ID: 35063467 [TBL] [Abstract][Full Text] [Related]
6. Untargeted metabolic profiling identifies interactions between Huntington's disease and neuronal manganese status. Kumar KK; Goodwin CR; Uhouse MA; Bornhorst J; Schwerdtle T; Aschner M; McLean JA; Bowman AB Metallomics; 2015 Feb; 7(2):363-70. PubMed ID: 25599126 [TBL] [Abstract][Full Text] [Related]
7. A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease. Tidball AM; Bryan MR; Uhouse MA; Kumar KK; Aboud AA; Feist JE; Ess KC; Neely MD; Aschner M; Bowman AB Hum Mol Genet; 2015 Apr; 24(7):1929-44. PubMed ID: 25489053 [TBL] [Abstract][Full Text] [Related]
9. Mitochondrial and redox modifications in early stages of Huntington's disease. Lopes C; Ferreira IL; Maranga C; Beatriz M; Mota SI; Sereno J; Castelhano J; Abrunhosa A; Oliveira F; De Rosa M; Hayden M; Laço MN; Januário C; Castelo Branco M; Rego AC Redox Biol; 2022 Oct; 56():102424. PubMed ID: 35988447 [TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516 [TBL] [Abstract][Full Text] [Related]
11. Huntington's disease associated resistance to Mn neurotoxicity is neurodevelopmental stage and neuronal lineage dependent. Joshi P; Bodnya C; Ilieva I; Neely MD; Aschner M; Bowman AB Neurotoxicology; 2019 Dec; 75():148-157. PubMed ID: 31545971 [TBL] [Abstract][Full Text] [Related]
12. Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model. Buren C; Tu G; Raymond LA J Huntingtons Dis; 2020; 9(2):149-161. PubMed ID: 32310183 [TBL] [Abstract][Full Text] [Related]
13. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402 [TBL] [Abstract][Full Text] [Related]
14. Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders. Bryan MR; Bowman AB Adv Neurobiol; 2017; 18():113-142. PubMed ID: 28889265 [TBL] [Abstract][Full Text] [Related]
15. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model. Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125 [TBL] [Abstract][Full Text] [Related]
16. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655 [TBL] [Abstract][Full Text] [Related]
18. Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington's Disease Mice. Berggren KL; Lu Z; Fox JA; Dudenhoeffer M; Agrawal S; Fox JH J Huntingtons Dis; 2016; 5(1):53-63. PubMed ID: 27079948 [TBL] [Abstract][Full Text] [Related]
19. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655 [TBL] [Abstract][Full Text] [Related]
20. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model. Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]